Dosing
    Semaglutide
    Starter Dose

    Semaglutide 0.25 mg: The Starter Dose (Weeks 1-4 Guide)

    0.25 mg is where every Wegovy and compounded semaglutide regimen begins. It's not the therapeutic dose — it's the gut-tolerance dose that makes the therapeutic dose possible.

    Last updated: May 12, 20267 min read

    Semaglutide 0.25 mg is the FDA-required starter dose for Wegovy chronic weight management and the standard starting point for compounded semaglutide. It's intentionally sub-therapeutic — at 0.25 mg, semaglutide doesn't deliver the full 15-17% body-weight reduction Wegovy showed in the STEP 1 NEJM 2021 trial. What it does is prime your GLP-1 receptors and let your gut adapt to delayed gastric emptying without the severe nausea that would happen if you started at a therapeutic dose.

    What 0.25 mg does (and doesn't)

    At 0.25 mg weekly, semaglutide partially activates GLP-1 receptors throughout the gut, pancreas, and central nervous system. Appetite is mildly suppressed. Gastric emptying slows by 20-40%. Some patients lose 1-3 lbs in the first 4 weeks; others lose none. This is normal and expected — the goal of weeks 1-4 isn't weight loss, it's tolerance building.

    The standard Wegovy escalation: 0.25 mg (weeks 1-4) → 0.5 mg (weeks 5-8) → 1.0 mg (weeks 9-12) → 1.7 mg (weeks 13-16) → 2.4 mg (weeks 17+ maintenance). Each step approximately doubles the GLP-1 receptor activation and the appetite-suppression effect. Therapeutic weight loss starts at 0.5-1.0 mg and peaks at 2.4 mg.

    Side effects at 0.25 mg

    Most patients experience some mild nausea, fatigue, decreased appetite, or constipation in weeks 1-2 as the gut adapts. By week 3-4, these typically fade. Severe side effects (vomiting requiring fluids, persistent diarrhea) are uncommon at 0.25 mg — if they happen, hold at this dose longer before escalating, or contact your clinician.

    Trimi 0.25 mg starter protocol

    • • Inject once weekly on the same day each week (subcutaneous: abdomen, thigh, or upper arm)
    • • Rotate injection sites week-to-week to reduce local skin reactions
    • • Stay hydrated (target 80+ oz water/day) — helps with nausea and constipation
    • • High-protein meals (~30g per meal) reduce nausea triggers
    • • Plan 4 weeks at 0.25 mg before considering escalation to 0.5 mg

    Start semaglutide 0.25 mg with Trimi

    $99/month annual plan, flat across all titration doses. US-licensed clinicians, free expedited shipping, 503A pharmacy.

    Start your visit

    FAQs

    Will I lose weight on semaglutide 0.25 mg?

    Modestly. 0.25 mg is the starter dose — it primes your GLP-1 receptors but doesn't deliver the full appetite-suppression effect. Most patients on 0.25 mg for the first 4 weeks see 1-3 lbs of weight loss; the bigger drop comes after escalating to 0.5 mg, 1.0 mg, and beyond. Per the STEP 1 trial protocol (NEJM 2021), 0.25 mg is a tolerance-building dose, not a therapeutic-effect dose.

    Why start at 0.25 mg instead of going straight to 2.4 mg?

    GI tolerance. Going straight to a therapeutic semaglutide dose causes severe nausea, vomiting, and diarrhea in most patients. The 4-week 0.25 mg starter period lets your gut adapt to delayed gastric emptying and central GLP-1 effects gradually. Per the FDA-approved Wegovy prescribing information, the dose-escalation schedule is mandatory for tolerability.

    How long do I stay on 0.25 mg?

    4 weeks (weeks 1-4) per the standard Wegovy/Ozempic titration protocol. After 4 weeks at 0.25 mg, clinicians typically escalate to 0.5 mg. If you experience severe GI side effects, you can hold at 0.25 mg for an additional 2-4 weeks before escalating — Trimi clinicians adjust based on individual tolerance.

    Will I have side effects at 0.25 mg?

    Some patients experience mild nausea, decreased appetite, fatigue, or constipation in weeks 1-2 as the gut adapts. Most side effects fade by week 3-4. The starter dose is specifically designed to be the most tolerable dose of the titration — if you can't tolerate 0.25 mg, escalating to 0.5+ mg will be worse.

    Can I stay on 0.25 mg long-term?

    Not typically. 0.25 mg is sub-therapeutic for sustained weight management. Patients who plateau quickly and want to maintain at a low dose usually settle at 1.0 mg, not 0.25 mg. If you need a slower titration for tolerability reasons, hold at each step longer rather than staying indefinitely at 0.25 mg.

    Is 0.25 mg the same in Wegovy, Ozempic, and compounded semaglutide?

    Yes — 0.25 mg is the same active ingredient and dose across all three. The semaglutide molecule is identical. Wegovy and Ozempic are pre-filled pen autoinjectors with 0.25 mg dose-set; compounded semaglutide (via Trimi and similar) is drawn into a syringe from a vial — the patient draws 0.25 mg from the vial concentration. Clinician walks you through the math during onboarding.

    How much does semaglutide 0.25 mg cost?

    Wegovy 0.25 mg pen list price is approximately $1,349/month — same as any other dose strength because Wegovy is priced per pen, not per mg. Compounded semaglutide via Trimi is $99/month on annual plan, $175/month on month-to-month, flat across all titration doses (0.25 mg through 2.4 mg).

    Related reading

    Disclaimer: Informational, not medical advice. Compounded semaglutide is prepared per individual prescription by a 503A community sterile compounding pharmacy; not FDA-approved as a finished drug (active ingredient is FDA-approved in Wegovy and Ozempic). Always consult a licensed clinician about dose titration. **The FDA does not review or approve any compounded medications for safety or effectiveness.

    What does the published clinical evidence show for compounded semaglutide?

    Peer-reviewed evidence: Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021). Trimi offers compounded semaglutide starting at $99/month on the annual plan, dispensed by 503A community sterile compounding pharmacies (VialsRx — Texas pharmacy license #35264 — and GreenwichRx). Results vary by individual; eligibility is determined by a licensed clinician.

    Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. — STEP 1, NEJM 2021
    Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. — STEP 4, JAMA 2021
    Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. — SELECT, NEJM 2023

    Key Takeaways

    • Adults with overweight or obesity on semaglutide 2.4 mg achieved a mean body weight reduction of approximately 14.9% at 68 weeks, compared with 2.4% on placebo. (Source: STEP 1, NEJM 2021)
    • Approximately 86% of patients on continued semaglutide treatment maintained ≥5% body-weight reduction from baseline through 68 weeks, vs 33% in the placebo-switch arm. (Source: STEP 4, JAMA 2021)
    • Semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% over a mean 39.8-month follow-up in adults with overweight/obesity and pre-existing cardiovascular disease without diabetes. (Source: SELECT, NEJM 2023)
    • Semaglutide is the active pharmaceutical ingredient; it is FDA-approved in the corresponding brand finished products (Wegovy and Ozempic). Trimi's compounded preparation of the same active ingredient is prepared per individual prescription by 503A community sterile compounding pharmacies and is not itself FDA-approved as a drug.
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: March 1, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    2. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA.Read StudyDOI: 10.1001/jama.2021.3224
    3. Garvey WT, Batterham RL, Bhatta M, et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine.Read StudyDOI: 10.1038/s41591-022-02026-4
    4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2307563
    5. Marso SP, Bain SC, Consoli A, et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa1607141
    6. Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2403347

    Was this article helpful?

    Keep Reading

    Complete guide to semaglutide 0.25mg starting dose. Learn what to expect during your first 4 weeks, common side effects, expected weight loss, and when to increase your dose.

    Everything you need to know about semaglutide 7.2mg, the higher-dose formulation. Learn about clinical trial results showing 20-24% weight loss, titration from 2.4mg, side effects, and who qualifies.

    Complete guide to semaglutide 1.7mg dosing. Learn about expected weight loss results, side effects at this higher dose, and how to decide between staying at 1.7mg or advancing to 2.4mg.

    Deep dive into semaglutide 1.0mg dose. Learn why this is where significant weight loss begins, what results to expect, side effect management, and whether to advance to 1.7mg.

    Start your GLP-1 journey — from $99/mo

    Get Started